Skip to content
Screener

G&A at other companies

Pediatrix Medical Group logo
Pediatrix Medical GroupMD
$60.27M+2.8%
Sera Prognostics logo
Sera PrognosticsSERA
$4.29M-3.5%
GoodRx Holdings, Inc. logo
GoodRx Holdings, Inc.GDRX
$24.81M-12.6%
Myriad Genetics logo
Myriad GeneticsMYGN
$62.2M-6.5%
LifeMD, Inc. logo
LifeMD, Inc.LFMD
$15.18M+5.8%
Privia Health Group, Inc. logo
Privia Health Group, Inc.PRVA
$39.66M+5.7%

Segments

By segment

See full
Reportable segment$31.22M-13.8%

Other financials

Income statement

See full
Revenue$350.5M+5.3%
Gross profit$89.3M+13.1%
Operating income$40.0M+64.2%
Net income$28.1M+63.9%
EPS (diluted)$0.34+78.9%

Balance sheet

See full
Cash & equivalents$152.6M+15.2%
Total debt$27.0M-5.8%
Total equity$453.3M-12.0%
Total assets$715.8M-5.9%

Cash flow

See full
Operating cash flow$50.4M-9.2%
CapEx$6.2M+18.0%
Free cash flow$44.2M-12.0%

Valuation

See full
Market cap$2.37B+17.5%
Enterprise value$2.24B+17.3%
P/E30.1×-7.8×
P/S1.8×+0.2×

Profitability

See full
Gross margin24.6%+2.2pp
Operating margin8.6%+2.4pp
Net margin6%+1.7pp
FCF margin13.6%-1.7pp

Returns & leverage

See full
Return on equity16.2%+5.3pp
Debt / equity0.1×0.0×
Current ratio2.1×-0.6×

Where this comes from

Reported directly by Progyny in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Progyny’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 9:00 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001551306-26-000140
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gross profit89,30178,973172,372154,768
Operating expenses:
Sales and marketing18,07418,40534,95836,191
General and administrative31,22436,21062,03270,049
Total operating expenses49,29854,61596,990106,240
Income from operations40,00324,35875,38248,528
Interest and other income, net1,1342,7192,6385,086
Income before income taxes41,13727,07778,02053,614

Item 1. Financial Statements (Unaudited)

FAQ

What is Progyny's G&A?
Progyny (PGNY) reported G&A of $31.22M in Q2 2026.
How has Progyny's G&A changed year-over-year?
Progyny's G&A decreased by 13.8% year-over-year, from $36.21M to $31.22M.
What is the long-term trend for Progyny's G&A?
Over 4 years (2021 to 2025), Progyny's G&A has grown at a 25.3% compound annual growth rate (CAGR), from $59.62M to $147.09M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about Progyny's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude